Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo.
In view of the effectiveness of antimalaria drugs inhibiting abnormal protease-resistant prion protein (PrP-res) formation in scrapie agent-infected cells, we tested other antimalarial compounds for similar activity. Mefloquine (MF), a quinoline antimalaria drug, was the most active compound tested against RML and 22L mouse scrapie agent-infected cells, with 50% inhibitory concentrations of approximately 0.5 and approximately 1.2 microM, respectively. However, MF administered to mice did not delay the onset of intraperitoneally inoculated scrapie agent, the result previously observed with quinacrine. While most anti-scrapie agent compounds inhibit PrP-res formation in vitro, many PrP-res inhibitors have no activity in vivo. This underscores the importance of testing promising candidates in vivo.
Kocisko
David A
DA
National Institute of Allergy & Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA. dkocisko@niaid.nih.gov
Caughey
Byron
B
D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D007274:Injections, Intraperitoneal; D015767:Mefloquine / Q000008:administration & dosage* / Q000494:pharmacology; D051379:Mice; D010447:Peptide Hydrolases / Q000378:metabolism; D011328:Prions / Q000037:antagonists & inhibitors / Q000378:metabolism; D012608:Scrapie / Q000517:prevention & control*
D000962:Antimalarials; D011328:Prions; D010447:Peptide Hydrolases; D015767:Mefloquine